Latest News

Stay up to date with the latest developments in myasthenia gravis research, advocacy, and community support. Explore news, events, and policy updates to stay informed and get involved.

Browse our categories to explore stories relevant to you, and stay connected with the MG community.

All
  • All
  • About MAA News Items
  • Annual Conference News Items
  • Art With Heart News Items
  • Get Involved News Items
  • Health Professionals News Items
  • Living with MG News Items
  • MG Awareness Month News Items
  • Patient Tool Kit
  • Policy Makers News Items
  • Understanding MG News Items
Recruitment-Image-1-17.9.24
Last Chance to Participate

Last opportunity to participate in MG and Work survey – closing 17thFebruary 2025 The MAA has partnered with the University of the Sunshine Coast to conduct research on Myasthenia Gravis and people’s ability to work. The research team is led by Dr. Michele Verdonck. MG can significantly affect people’s ability to work. Little is understood…

7.-PBAC-Submission-Final-Reminder-1024x734
Last chance to make your submission to PBAC!

This is a final reminder that the patient/consumer submissions to PBAC (Pharmaceutical Benefits Advisory Committee) close at 11pm on Wednesday 29 January 2025!  Make your submission(s) via the online form here.  These submissions will contribute to the PBAC meeting in March where they will consider 4 new treatments for Myasthenia Gravis (MG) being available and accessible in…

6.-PBAC-Submission-Time-for-your-Submission-1024x734 (1)
Time for your Submission to PBAC

A big thank you to everyone who attended and participated in our webinar on 15 January. For those who registered but couldn’t join at the time, please check your emails for a link to the recording.  If you haven’t done so already, now is the time to make your submission to PBAC about new treatments for Myasthenia…

4.-Webinar-Register-here-1024x734
Last chance! MAA webinar registrations are closing

Don’t hesitate for one more minute! Register here for the Myasthenia Alliance Australia (MAA) webinar to learn about new treatments for generalised Myasthenia Gravis. You may be offered new treatments in the future and this webinar will help you understand what these treatments are and how they may benefit you.  The webinar will be held at 5:30pm (AEDT)/4.30pm (AEST) on Wednesday 15…

4.-Webinar-Register-here-1024x734
Register NOW for the MAA webinar on new treatments for Myasthenia!

It is a new year and we have a once in a generation opportunity for new treatments for Myasthenia Gravis! The Pharmaceutical Benefits Advisory Committee (PBAC) will assess 4 new treatments for generalised Myasthenia Gravis (gMG) at its meeting in March 2025. You can make a personal submission by 29 January 2025 highlighting your lived experience as a Myasthenia patient to add…

3.-PBAC-Submission-Rozanolixizumab-1024x734 (1)
PBAC submissions for Rystiggo® (Rozanolixizumab) for all Myasthenia Gravis patients

The Australian Myasthenia community have a once in a generation opportunity to support new treatments for generalised Myasthenia Gravis (gMG) which are listed on PBAC’s March 2025 agenda! The Myasthenia Alliance Australia (MAA) encourages Myasthenia patients and your carers or families/friends to consider making a personal submission highlighting your lived experience by 29 January 2025.…

2.-PBAC-Submission-Efgartigimod-1024x734
PBAC submissions for Vyvgart® (efgartigimod alfa) for all Myasthenia Gravis patients

The Australian Myasthenia community have a once in a generation opportunity to support new treatments for generalised Myasthenia Gravis (gMG) which are listed on PBAC’s March 2025 agenda!  The Myasthenia Alliance Australia (MAA) encourages Myasthenia patients and your carers or families/friends to consider making a personal submission highlighting your lived experience by 29 January 2025. Why? Because…

1.-PBAC-Submission-Ravulizumab-and-Zilucoplan-1024x734
PBAC resubmissions for Ultomiris® (Ravulizumab) and Zilbrysq® (Zilucoplan) for all Myasthenia Gravis patients

The Australian Myasthenia community have a once in a generation opportunity to support new treatments for generalised Myasthenia Gravis (gMG) which are listed on PBAC’s March 2025 agenda! The Myasthenia Alliance Australia (MAA) encourages Myasthenia patients and your carers or families/friends to consider making a personal submission highlighting your lived experience by 29 January 2025. Why? Because…

PBAC-Time-to-Act
It is time to act! The PBAC lists 4 new gMG treatments for consideration at the March 2025 meeting!

The Pharmaceutical Benefits Advisory Committee (PBAC) has published its agenda for March 2025 and there are 4 generalised Myasthenia Gravis (gMG) treatments for consideration. Two are resubmissions and the other two are new requests for PBS listings. You can see the full agenda here. The closing date for consumer comments is Wednesday, 29th January 2025. The MAA…

MAA-ECU
Coming in the New Year – exciting new research opportunity!

The MAA and Edith Cowan University are collaborating to explore the health journey of people with MG from diagnosis through to living with the condition. Online workshops will be conducted to understand people’s experiences of living with MG.